A2 Bio key facts
as of Oct 2026- Developer of a cell therapy designed to cure cancer via tumor-specific targeting.
- A2 Bio is valued at approximately $280.0M as of Oct 2026 (last reported valuation).
- It has raised $352.9M; the latest was Later Stage VC ($80.0M) in Jan 2025.
- Notable investors include Mana Ventures, StepStone Group, S32, Samsara BioCapital, Casdin Capital — 15 tracked in total.
- Status: Privately Held (backing).
A2 Bio's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch A2 Bio: the Monday email on marks, rounds and moves
A2 Bio funding rounds
No funding rounds for A2 Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs A2 Bio
15+Membership and data by Private Market View
A2 Bio valuation
A2 Bio's last reported valuation was $280 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
A2 Bio investors
15 investors are on record for A2 Bio, including Mana Ventures, StepStone Group, S32 and Samsara BioCapital. By type, the record holds 4 venture capital firms and 1 family office.
About A2 Bio
Developer of a cell therapy designed to cure cancer via tumor-specific targeting. The company engineers tumor cells that target the loss of genetic material in tumors through the selective killing of tumor cells while leaving normal cells unharmed, enabling physicians to revolutionize the treatment of solid tumors.
- Sector
- Healthcare
- HQ
- Agoura Hills, CA, United States
- Founded
- 2017
- Employees
- 124
- Website
- a2bio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.